Evidence map›Paper›PMID 31462709›Full record

ArticleOncogene2020

TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment.

Sherona R Sirkisoon, Richard L Carpenter, Tadas Rimkus, Daniel Doheny, Dongqin Zhu, Noah R Aguayo, Fei Xing, Michael Chan, Jimmy Ruiz, Linda J Metheny-Barlow and 9 more

Erratum issuedAbstract read
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Sherona R SirkisoonDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Richard L CarpenterDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Tadas RimkusDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Daniel DohenyDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Dongqin ZhuDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Noah R AguayoDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Fei XingDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Michael ChanComprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Jimmy RuizComprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Linda J Metheny-BarlowComprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Roy StrowdComprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Jiayuh LinDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA.
Angelina T ReguaDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Austin ArrigoDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Marlyn AnguelovDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Boris PascheDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID http://orcid.org/0000-0002-3750-7898
Waldemar DebinskiDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Kounosuke WatabeDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Hui-Wen LoDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA. hlo@wakehealth.edu.
Wake Forest University · USIndiana University Bloomington · USUniversity of Maryland, Baltimore · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Training Program in Cancer BiologyT32CA079448 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KRIDEL, STEVEN J. · 2000 to 2014
$6.5M
Truncated GLI1 In GlioblastomaR01NS087169 · NINDS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LO, HUI-WEN · 2014 to 2018
$2.1M
Roles of tGLI1 and microRNA Network in Breast Cancer Brain MetastasisR01CA228137 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LO, HUI-WEN, WATABE, KOUNOSUKE · 2020 to 2025
$2.1M
Role of Truncated GLI1 in Glioma Stem CellsF31CA224805 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SIRKISOON, SHERONA R. · 2018 to 2018
$36k
NCI NIH HHS F31 CA224805NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA228137NCI NIH HHS T32 CA079448NINDS NIH HHS R01 NS087169
6 · The paper itself

Abstract

Mechanisms for breast cancer metastasis remain unclear. Whether truncated glioma-associated oncogene homolog 1 (TGLI1), a transcription factor known to promote angiogenesis, migration and invasion, plays any role in metastasis of any tumor type has never been investigated. In this study, results of two mouse models of breast cancer metastasis showed that ectopic expression of TGLI1, but not GLI1, promoted preferential metastasis to the brain. Conversely, selective TGLI1 knockdown using antisense oligonucleotides led to decreased breast cancer brain metastasis (BCBM) in vivo. Immunohistochemical staining showed that TGLI1, but not GLI1, was increased in lymph node metastases compared to matched primary tumors, and that TGLI1 was expressed at higher levels in BCBM specimens compared to primary tumors. TGLI1 activation is associated with a shortened time to develop BCBM and enriched in HER2-enriched and triple-negative breast cancers. Radioresistant BCBM cell lines and specimens expressed higher levels of TGLI1, but not GLI1, than radiosensitive counterparts. Since cancer stem cells (CSCs) are radioresistant and metastasis-initiating cells, we examined TGLI1 for its involvement in breast CSCs and found TGLI1 to transcriptionally activate stemness genes CD44, Nanog, Sox2, and OCT4 leading to CSC renewal, and TGLI1 outcompetes with GLI1 for binding to target promoters. We next examined whether astrocyte-priming underlies TGLI1-mediated brain tropism and found that TGLI1-positive CSCs strongly activated and interacted with astrocytes in vitro and in vivo. These findings demonstrate, for the first time, that TGLI1 mediates breast cancer metastasis to the brain, in part, through promoting metastasis-initiating CSCs and activating astrocytes in BCBM microenvironment.

Indexed as

AnimalsAstrocytesBrain NeoplasmsBreast NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHeterograftsHumansHyaluronan ReceptorsLymphatic MetastasisMiceNanog Homeobox ProteinNeoplastic Stem CellsOctamer Transcription Factor-3ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGLI1 protein, humanHyaluronan ReceptorsNanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3POU5F1 protein, humanSOX2 protein, humanSOXB1 Transcription FactorsTranscription FactorsZinc Finger Protein GLI1

Identifiers

PMID31462709
PMCPMC6938539
OpenAlexW2970757780

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.